ArticleFrontiers in nutrition2026
Omega-3 polyunsaturated fatty acid intake and pain, inflammatory cytokines, and quality of life in endometriosis.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endometriosis: Epidemiology, Risk Factors, Molecular Mechanisms, Diagnosis, and Management.MedComm · 2026Review
- Acupuncture Combined with Herbal Cake-Separated Moxibustion for Chronic Pelvic Pain in Sequelae of Pelvic Inflammatory Disease: Study Protocol for a Randomized Controlled Trial.Journal of pain research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis is a chronic inflammatory gynecologic disorder associated with pelvic pain and impaired health-related quality of life (HRQoL). Omega-3 polyunsaturated fatty acids (PUFAs) have anti-inflammatory potential and may confer adjunctive benefit when combined with conventional therapy. This study evaluated the association between adjunctive omega-3 PUFA intake and pain, inflammatory biomarkers, and HRQoL in endometriosis. Methods: This retrospective, time-period-based cohort study included patients with confirmed endometriosis treated at a single center between January 2021 and December 2024. Conventional therapy during 2021-2022 served as the control period, whereas conventional therapy plus omega-3 PUFA supplementation during 2023-2024 constituted the exposure period. Outcomes included pain assessed by the visual analog scale (VAS), inflammatory biomarkers [interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and C-reactive protein (CRP)], and HRQoL measured using the 36-Item Short Form Health Survey (SF-36), including the Physical Component Summary (PCS) and Mental Component Summary (MCS). Multivariable logistic regression and inverse probability of treatment weighting (IPTW) were applied, with pre-specified subgroup and sensitivity analyses. Results: Among 302 screened patients, 289 were analyzed (control Conclusions: Adjunctive omega-3 PUFA intake was associated with improved pain, reduced inflammatory biomarkers, and better HRQoL in endometriosis, warranting confirmation in future prospective randomized studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.